American Society of Hematology

Figure 4.

$Figure 4. The effect of suffused UFH on PAR-1 agonist peptide-reduced sickle RBC flow velocity (VRBC). Results are described as VRBC of XRITC-labeled sickle RBCs in C57/BL (control) mice. (A) VRBC of sickle RBCs in PAR-1 agonist peptide (PAR-1ap)-treated venules prior to and after UFH suffusion (heparin rescue). Results are of individual VRBC changes in single venules from 5 different experiments. (B) Real-time course plots of RBC velocity (VRBC) in medium (20 to 40 μm) and large (40 μm to 80 μm) venules in C57BL/6 (control) mice treated with inactive scrambled PAR-1 agonist peptide (sPAR-1ap), active PAR-1 agonist peptide (PAR-1ap), and unfractionated heparin (heparin).$

The effect of suffused UFH on PAR-1 agonist peptide-reduced sickle RBC flow velocity (V_RBC). Results are described as V_RBC of XRITC-labeled sickle RBCs in C57/BL (control) mice. (A) V_RBC of sickle RBCs in PAR-1 agonist peptide (PAR-1ap)-treated venules prior to and after UFH suffusion (heparin rescue). Results are of individual V_RBC changes in single venules from 5 different experiments. (B) Real-time course plots of RBC velocity (V_RBC) in medium (20 to 40 μm) and large (40 μm to 80 μm) venules in C57BL/6 (control) mice treated with inactive scrambled PAR-1 agonist peptide (sPAR-1ap), active PAR-1 agonist peptide (PAR-1ap), and unfractionated heparin (heparin).

This Feature Is Available To Subscribers Only